Tilray secures approval regarding US clinical trial, share price soars

By baddey dey`
Share
Canadian cannabis producer Tilray Inc has received approval from the US Drug Enforcement Agency (DEA) to import a cannabis product to the US for a clinical trial at the University of California, San Diego
 
The news has seemingly prompted another spike in the company’s share price, improving by 30% on 18 September and pushing their value to an increase of over 800% since the IPO launch.
 
Financial Post said that this has boosted the company’s market valuation to “about US$14.4 billion”, placing it well above previous leader Canopy Growth Corp at “around US$11.5 billion”.
 
According to CNBC, the clinical trial in San Diego will “study the safety, tolerability and efficacy of marijuana for a neurological disorder”.
 
Tilray CEO Brendan Kennedy said of the trial’s impact on the company’s prospects:
 
“Clinical trials build a halo around the brand”.
 
See more:
 
 
“They inspire confidence and trust with physicians and regulators around the world and they give us data and information to talk to pharmacists and physicians that they just can’t obtain from our competitors”.
 
Canada’s fast-approaching legalization of recreational cannabis use has thus far seen stocks across the industry jump in value, though Tilray’s market growth is particularly remarkable.
 
Companies including Coca-Cola are keen to cash-in on the emerging market, with the soft drink company reportedly interested in producing cannabis-infused products.
Share

Featured Articles

Over Half of US CEOs Back Trump to Boost Global Economy

52% of US CEOs pick Donald Trump over Kamala Harris when it comes to boosting the world economy. CEOs outside of America though are equally divided

Why the Cloud is Murky for Microsoft CEO Satya Nadella

On the face of it, demand has never been higher for Microsoft Azure’s data-centre capacity. So why is Microsoft forecasting slower cloud revenue growth?

Businesses Are Scapegoat in UK Budget Tax Rises

Owners of larger businesses will shoulder burden of almost all this year’s £25bn tax hike, leading to estimated 50,000 job losses and lower pay awards

What Can McDonald's CEO Do to Win Back Trust?

Leadership & Strategy

5 Things Spelling Trouble for Alphabet CEO Sundar Pichai

Technology & AI

How Standard Chartered CEO Bill Winters Is Shaking Things Up

Leadership & Strategy